LONG-ACTING DRUG DELIVERY TECHNOLOGIES AND SERVICES

Long-acting drug delivery has emerged as the novel and advanced drug delivery system which manipulate the dosing regimen of the drug in the body in order to sustain its therapeutic level.

Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to the long-acting drug delivery of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases. The long-acting delivery of drug candidates confers several advantages, such as improved patient compliance, reduced dosage requirement, ****ter medication adherence, decrease in failure risk due to inconsistent usage and more convenience to patients. In addition, long acting drug delivery formulations can improve the chemical stability, solubility and polymorphic transformation issues of the active pharmaceutical ingredients.

To request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis.com/....reports/long-acting-

Lately, many technologies are being explored to develop long-acting drugs in various dosage formats, such as long-acting injectables, depot injections, implantable devices and combination products. The long-acting drug delivery technologies have come a long way with the inclusion of liposomes, microspheres and polymers for the fabrication of biodegradable and biocompatible delivery system. Apart from this, the interdependency of drug, excipient and release environment plays a crucial role to decide the release kinetics of the drug. Long-acting formulations are more patient compliant, in terms of sharp reduction in the dosing regimen. These drugs are administered infrequently (ranging from once weekly to yearly) owing to the prolonged drug release after a single shot.

The technological advancements for the long-acting profile of the drugs (small molecules, peptides, biologics) have led to the rise in number of novel therapeutics in the market along with the growing number of long-acting molecules in the clinical development pipeline. Of late, the demand for the availability of long-acting vaginal rings as multipurpose prevention technologies for women is also surfacing. Further, the pharmaceutical industry is extensively focusing on the development of long-acting injectables for protein-based drugs and multidrug therapies. Moreover, the potential of long acting injectables is being explored in several debilitating chronic diseases, such as Alzheimer’s, Parkinson’s disease, blindness and HIV. Owing to the advanced LADD technologies, formulation and developmental challenges associated with these complex dosage forms, the reliability on the stakeholders having the expertise in this domain has upsurged. This will eventually aid the drug developers to address the bottlenecks stemming from conventional treatment options and improve the clinical outcome.

For additional details, please visit
https://www.rootsanalysis.com/....reports/long-acting- or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

The smart pharmaceutical and healthcare labels market is anticipated to grow at a CAGR of 16%, till 2035, claims Roots Analysis

In order to overcome the limitations and challenges related to counterfeit drugs, researchers and industry stakeholders are gradually adopting smart pharmaceutical and healthcare labels, which offer multiple benefits over conventional labels.

Roots Analysis has announced the addition of “Smart Pharmaceutical and Healthcare Labels Market, 2022-2035” report to its list of offerings.

A smart label comprises of printed information, a bar code identifier and a small transponder. This transponder contains a processing chip and an antenna that allows physical objects to communicate with the tag reader (for instance, RFID reader). Smart labels offer several benefits, such as tracing and tracking products in a supply chain, tamper proofing, as well as discouraging counterfeiters from packaging fake drugs. In this context, it is worth mentioning that smart labelling technology can potentially save USD 0.8 - 1.5 million per year, per company, through their applications in inventory management.


Key Market Insights

More than 90 companies claim to offer smart pharmaceutical and healthcare labels, globally
This segment of the industry is dominated by the presence of mid-sized (51-500 employees) and small (less than 50 employees) players, which collectively represent more than 75% of the total smart label providers in pharmaceutical and healthcare sectors. Further, ~20% of firms were established post-2010.

400+ patents related to smart pharmaceutical and healthcare labels were filed / granted, since 2015
Based on intellectual property distribution across the world, R&D activity related to smart pharmaceutical and healthcare labels is largely concentrated in North America (over 65%), followed by Europe (10%). In addition, most of the patents have been granted patent (55%), followed by patent applications (44%).

Partnership activity in this domain has increased at a significant pace, ****ween 2018 and 2022
The recent partnerships trend in this market indicates the growing interest of industry stakeholders. It is worth highlighting that majority of the deals were service alliances, representing around 41% of the total number of partnerships signed in the given time period.

North America and Europe are anticipated to capture over 65% of the market share by 2035
The markets in Asia-Pacific and Latin America are anticipated to grow at a relatively faster pace. In the long-term, the aforementioned regions are expected to collectively represent 33% of the total market share. In addition, RFID based smart labels are likely to capture more than 75% of the market share in 2035.

To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/....reports/smart-labels

Key Questions Answered
 Who are the leading players engaged in the development of smart pharmaceutical and healthcare labels?
 What is the relative competitiveness of different smart pharmaceutical and healthcare labels providers?
 Which types of partnership models are most commonly being adopted by stakeholders engaged in this domain?
 What are the key strategies that can be implemented by emerging players / start-ups to enter the highly competitive market for smart labels for the healthcare sector?
 Which companies are actively filing patents to drive innovation in the field of smart pharmaceutical and healthcare labels?
 What are the key challenges within the smart pharmaceutical and healthcare labels market?
 What is the current / likely future market size of smart pharmaceutical and healthcare labels?


The financial opportunity within the smart pharmaceutical and healthcare labels market has been analyzed across the following segments:

 Type of Technology
 RFID
 NFC
 Other Technologies

 Type of packaging
 Primary Packaging
 Secondary Packaging

 Type of Primary Packaging
 Vials
 Syringes
 Cartridges
 Ampoules
 Bottles
 Blister Packs

 Type of Secondary Packaging
 Boxes
 Cartons
 Pouches

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 MENA
 Latin America

The report includes detailed profiles of key players (listed below) engaged in providing smart pharmaceutical and healthcare labels; each profile features an overview of the developer, details related to smart labels focused product portfolio, recent developments and an informed future outlook:
 CCL Industries
 Schreiner
 Datalogic
 Tadbik
 SATO
 Invengo
 Intellhydro Technology
 RFiD Discovery
 ID Tech Solutions

For additional details, please visit https://www.rootsanalysis.com/....reports/smart-labels or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Pharmaceutical Secondary Packaging Market: Industry Trends and Global Forecast, 2022-2035
2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
ben.johnson@rootsanalysis.com

The SARM1 targeting therapeutics market is projected to grow at a CAGR of 102.1%, during the period 2033-2040, claims Roots Analysis

SARM1 inhibitors, having demonstrated the ability to prevent axonal degeneration, are being evaluated for the treatment of a number of neurodegenerative disorders. Once approved, these therapies are likely to capture a significant market share

Roots Analysis has announced the addition of “SARM1 Inhibitors Therapeutics Market, 2022 – 2040” report to its list of offerings.

Presently, several industry and non-industry stakeholders are evaluating SARM1 inhibitors as potential therapeutic agents for the treatment of neurological disorders across various preclinical studies and early stages of clinical development, worldwide. With the ongoing pace of innovation in this field, increasing R&D activity and promising pre-clinical data, several promising leads are anticipated to be commercially launched over the coming decade and SARM1 targeting therapeutics market is anticipated to witness substantial growth in the mid to long-term.

Key Market Insights

Presently, several SARM1 targeting therapy candidates are being developed by various industry players
About 65% of the pipeline candidates are currently being evaluated in the preclinical stages of development, followed by those currently in the discovery stage (35%). Further, it is worth mentioning that close to 85% of the SARM1 inhibitors are small molecules.

Currently, a number of companies claim to be engaged in the development of SARM1 inhibitors
The SARM1 inhibitors market is dominated by the presence of large companies (81%), followed by small players (19%). In addition, around 20% of the players were established post-2010.

120+ articles related to SARM1 inhibitors have been published ****ween 2011 and 2022
Majority (81%) of the articles published in this domain were research papers, followed by review papers (12%). It is important to note that more than 70% of the total number of articles were published post-2018.

Over 30 grants have been awarded for research related to SARM1 inhibitors, since 2014
Close to 40% of the total amount was awarded under the R01 mechanism (which supports research projects). Further, genetics and neurology emerged as the key research departments, having received 34% of the total grants, each.

70+ patents related to SARM1 targeting therapeutics have been filed / granted till 2022
Over the years, the number of patents filed for SARM1 inhibitors has increased gradually; majority of the patents have been filed / granted in 2021. Most of the patents in this domain are patent applications (96%), followed by granted patents (3%).

North America is anticipated to capture more than 65% share of the market, by 2040
By 2040, the market revenues are likely to be driven by the sales of small molecules (95%) being developed as SARM1 inhibitors. Further, sales of therapeutics targeting multiple sclerosis are likely to contribute to a majority share (~40%) of revenues, in the long term.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/sarm1-inhibi

Key Questions Answered
 Who are the leading players engaged in the development of SARM1 targeting therapeutics?
 What is the evolving trend of publications focused on SARM1 targeting therapeutics?
 How is the intellectual property landscape in this field likely to evolve in the foreseen future?
 What are the recent developments and strategic initiatives undertaken by players engaged in this market space related to the research and development of SARM1 targeting therapeutics?
 What are the key value drivers that are likely to influence the evolution of this upcoming market?
 How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the SARM1 targeting therapeutics market has been analyzed across the following segments:

 Type of Molecule
 Small Molecules
 Biologics

 Target Indication
 Multiple Sclerosis
 Peripheral, Central and Ocular Nervous System Disorders
 Peripheral Neuropathies
 Glaucoma
 Amyotrophic Lateral Sclerosis

 Drug Developers
 Company 1
 Company 2
 Company 3

 Drug Candidates
 Drug Candidate 1
 Drug Candidate 2
 Drug Candidate 3
 Drug Candidate 4
 Drug Candidate 5
 Drug Candidate 6

 Key Geographies
 North America
 Europe

The research includes detailed profiles of key players (listed below); featuring an overview of the company, financial information (if available), details related to its product portfolio, patent portfolio, recent developments (including partnerships and collaborations) and an informed future outlook.
 Disarm Therapeutics
 Nura Bio
 Washington University

For additional details, please visit
https://www.rootsanalysis.com/....reports/sarm1-inhibi
or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. RNAi Market: Therapeutics and Technologies (Focus on siRNA, miRNA, shRNA and DNA) (3rd Edition): Industry Trends and Global Forecasts, 2022-2035
2. Global Therapeutic Vaccines Market: Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

The dental 3D printing market is anticipated to grow at a CAGR of 15.1% during the period 2023-2035, claims Roots Analysis

The growing burden of dental diseases and the challenges associated with the conventional dental product manufacturing methods has significantly increased the adoption of 3D printing in the dental industry

Roots Analysis has announced the addition of “Dental 3D Printing Market, 2023 – 2035” report to its list of offerings.

The popularity of 3D printing technology within the dental industry can be attributed to its ability to print high quality / accurate dental products, including crowns, bridges, dentures, dental implants and surgical guides. Driven by the overall growth of the additive manufacturing (3D printing) industry, and wide adoption of 3D printers in the dental sector, the dental 3D printing market is anticipated to witness a steady growth in the foreseen future.


Key Market Insights

Currently, around 230 dental 3D printers are available for use across wide range of applications
Majority (38%) of the dental 3D printers use digital light processing (DLP) as printing technology, followed by those using stereolithography (SLA) technology (21%). Further, close to 75% of the dental 3D printers can produce crowns / bridges / dentures, followed by those manufacturing working models (61%) and surgical guides (59%). It is worth highlighting that around 55% of the dental 3D printers currently available in the market have a price range below USD 10,000.

More than 80 companies claim to offer dental 3D printers, across the world
Majority of the firms (46%) engaged in this domain are mid-sized players, followed by large (32%) and small firms (22%). It is worth highlighting that, more than 50% of the companies in this domain have been established post-2010. Further, around 85% of the dental 3D printer manufacturers are based in Asia-Pacific and Europe, followed by those headquartered in North America (16%), and within the Asia-Pacific region, China emerged as the most prominent hub, featuring the presence of maximum number of players (62%).

Partnership activity has grown at an annualized rate of over 70%, ****ween 2018-2022
Maximum number of partnerships were established in 2021 (56) and 2022 (44), indicating the recent surge in the partnership activity in this domain. Majority of these (26%) were product integration agreements. Further, most of the intercontinental as well as intracontinental deals have been inked by the players based in North America.

500+ patents related to dental 3D printing have been granted / filed ****ween 2019 and 2022
R&D activity related to dental 3D printing is largely concentrated in Asia-Pacific, considering the fact that 50% of the total number of patents were filed in this region. It is worth highlighting that, within the Asia-Pacific region, China emerged as the most active country with ~230 filed patents. In addition, most of the patents in this domain are patent applications (65%).

North America and Europe are anticipated to capture around 75% share of the market by 2035
In addition, the market in Asia-Pacific is likely to grow at a relatively faster pace (with CAGR of 16.3%) in the long term. Further, in 2035, based on type of printing technology, majority of the revenue share (64%) of the overall market is likely to be driven by vat polymerization technology. Further, in terms of application area, prosthodontics currently holds largest share (55%) of the market.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/dental-3d-pr

Key Questions Answered
 How is 3D printing used in the dental industry?
 How many dental 3D printers are currently available in the market?
 Which 3D printers are best for dentistry?
 What is the growth rate of the dental 3D printing market?
 Which region captures the largest share of the dental 3D printing market?
 Which printing technology is widely used in the dental 3D printers?
 Which application area currently holds the largest share in the dental 3D printing market?
 What are the partnerships and collaborations trend in the dental 3D printing domain?
 How many patents have been filed / granted related to dental 3D printing in the recent years?

The financial opportunity within the dental 3D printing market has been analyzed across the following segments:
 Type of Printing Technology
 VAT Polymerization Technology
 Powder Bed Fusion Technology
 Polyjet Technology
 Metal Extrusion Technology
 Other Technologies

 Application Area
 Prosthodontics
 Orthodontics
 Dental Implants
 Other Applications

 Type of Printing Material
 Resins
 Plastics
 Metals
 Metals
 Other Material

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Latin America
 Middle East and North Africa
 Rest of the World

The research also includes detailed profiles of key players (listed below) featuring a brief overview of the company, details related to dental 3D printer portfolio, recent developments, and an informed future outlook.
 3D Systems
 Asiga
 BEGO
 Carbon
 Digital Wax Systems (DWS)
 Formlabs
 Prodways
 Rapid Shape
 SprintRay
 Stratasys

For additional details, please visit
https://www.rootsanalysis.com/....reports/dental-3d-pr
or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
2. Medical Devices Contract Research Organizations Market (3rd Edition): Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.



Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com

The biologics fill / finish services market is projected to grow at a CAGR of 8%, till 2035, claims Roots Analysis

A number of biopharmaceutical companies are outsourcing their biologics fill / finish operations, thereby, prompting stakeholders engaged in this domain to undertake several expansion initiatives, to cater to the needs of clients around the globe.


Roots Analysis has announced the addition of “Biologics Fill Finish Services Market (3rd Edition), 2022-2035” report to its list of offerings.

Given the growing pipeline of biologics, lack of technical expertise, and huge capital investment in the installation of fill / finish equipment, a number of drug manufacturers are turning to contract service providers in order to ensure the development of quality drug products. This evident surge in the demand for biologics fill / finish services has presented lucrative opportunities for service providers having necessary fill / finish capabilities.



Key Market Insights

More than 175 service providers claim to offer services for biologic fill / finish operations
The biologics fill / finish market is highly fragmented, featuring a mix of small, mid-sized, and large players. It is worth noting that this market is currently dominated by mid-sized companies (having 51-500 employees), which represent more than 40% of the industry stakeholders, worldwide.

Several partnerships have been established in the biologics fill / finish services domain, since 2013
Nearly 40% of the deals were inked in 2020. Majority of the instances captured in the report were service agreements (60%). In addition, more than 50 deals have been inked by players to offer biologics fill / finish services for vaccines.

Over 170 expansions have been reported in biologics fill / finish services domain, since 2013
More than 50% of the total expansions were focused on enhancing the dedicated capacities, thereby enabling the industry stakeholders to accommodate their growing business and address the surge in the demand for fill / finish services. Further, more than 45% of the expansions involved the establishment of new plant / facilities or adding area to the existing facilities, across different geographical locations.

The currently available biologics fill / finish capacity is estimated to be over 185 Kiloliters
Around 90% of the installed fill / finish capacity belongs to the companies with commercial scale production capabilities. In fact, close to 85% of the available capacity belongs to the large companies (having more than 500 employees).

The demand for biologics fill / finish services is expected to grow at an annualized rate of 14%
Currently, more than 60% of the overall demand for biologics fill/ finish services is generated from filling of vials. Moreover, close to 40% of the demand is likely to be generated in the Europe region.

Europe and Asia-Pacific are expected to capture more than 70% of the market share by 2035
In terms of type of biologics, antibodies and vaccines are expected to occupy a larger share (~70%) of the total biologics fill / finish services market in 2035. Further, over 25% of the biologics fill / finish services market share for therapeutic areas is captured by oncological disorders.

To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/....reports/256/request-

Key Questions Answered
 What is fill / finish?
 Who are the key players offering biologics fill / finish services?
 Where are biologics fill / finish facilities located?
 What is the market share of ampoules, cartridges, vials, and syringes in fill / finish?
 What types of expansion initiatives are being undertaken by players in this domain?
 What is the current demand for biologics fill / finish services?
 What is the current and future market size for biologics fill / finish services?

The financial opportunity within the biologics fill / finish services market has been analyzed across the following segments:

 Type of Packaging Container
 Ampoules
 Cartridges
 Syringes
 Vials

 Type of Biologic
 Antibodies
 Cell Therapies
 Gene Therapies
 Oligonucleotides
 Proteins / Peptides
 Vaccines
 Others

 Therapeutic Area
 Oncological Disorders
 Autoimmune Disorders
 Infectious Diseases
 Cardiovascular Disorders
 Other Disorders

 Scale of Operation
 Preclinical / Clinical
 Commercial

 Company Size
 Large
 Mid-sized
 Small

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Middle East and North Africa
 Latin America

The report features inputs from eminent industry stakeholders, according to whom, a significant increase in the demand for cell and gene therapies is driving the growth of the biologics fill / finish market. The report includes detailed transcripts of discussions held with the following experts:

 Gregor Kawaletz (Chief Commercial Officer, IDT Biologika)
 Matt Delaney (Vice President Business Development & Marketing, Cytovance Biologics)
 Purushottam Singnurkar (Research Director and Head of Formulation Development, Syngene International)
 Ales Sima (Business Development Manager, Oncomed Manufacturing)
 Amit Chandra (Technology Watch Manager, Yposkesi)
 Jos Vergeest (International Business Developer, HALIX)

The research also includes detailed profiles of key players (listed below) engaged in offering biologics fill / finish services; each profile features a brief overview of the company, its financial information (if available), details on biologics fill / finish services, location of facilities recent developments and an informed future outlook.

 AbbVie Contract Manufacturing
 Asymchem
 BioReliance
 Boehringer Ingelheim BioXcellence
 Catalent Biologics
 Charles River Laboratories
 Fareva
 Fresenius Kabi
 Glaxo SmithKline
 Hetero Drugs
 Intas Pharmaceuticals
 Lonza
 Patheon
 Pierre Fabre
 Recipharm
 Samsun Biologics
 Syngene
 Takara Bio
 Wacker Biotech
 WuXi AppTec
 WuXi Biologics

For additional details, please visit
https://www.rootsanalysis.com/....reports/view_documen or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com